Central Nervous System News and Research

RSS

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

Strokes, seizures and other neurological complications related to heart surgery account for "considerable morbidity and mortality," Loyola University Health System neurologists report in the November issue of the journal Hospital Practice.

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Study finds extensive natural recovery after spinal cord injury

A study led by researchers in the Department of Neurosciences at the University of California, San Diego School of Medicine shows unexpected and extensive natural recovery after spinal cord injury in primates. The findings, to be published November 14 in the advance online edition of Nature Neuroscience, may one day lead to the development of new treatments for patients with spinal cord injuries.

15 Nov 2010

Research may lead to new treatment options for spinal cord injuries

15 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

The November 2010 issue of the Archives of Physical Medicine and Rehabilitation, Official Journal of the American Congress of Rehabilitation Medicine, has published a set of 9 articles on traumatic brain injury (TBI) that will accelerate future research in the field by establishing common language for the degree of injury, how it is measured and classified, treatment and potential outcomes.

12 Nov 2010

GPR124 protein controls growth of blood vessels into brains

One protein single-handedly controls the growth of blood vessels into the developing brains of mice embryos, according to researchers at the Stanford University School of Medicine. Understanding how the protein, a cellular receptor, functions could help clinicians battle brain tumors and stroke by choking off or supplementing vital blood-vessel development, and may enhance the delivery of drugs across the blood-brain barrier.

12 Nov 2010

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

The Genetics Policy Institute (GPI) today announced the launch of a new advocacy coalition of 30 organizations to foster public awareness and advance the cause of embryonic stem cell research in the United States.

12 Nov 2010

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

StemCellRegenMed, Inc. announces that a new stem cell gene and enzyme replacement treatment has been performed on a fourteen month old child with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a devastating disease that afflicts children primarily of parents of Jewish heritage and in very rare cases families of Eastern European background and the Cajun region in the U.S.A.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP).

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

Excess levels of TNF immune signaling protein key factor in AD

Three new studies provide converging evidence pointing to a new therapeutic target in Alzheimer's Disease(AD). These studies, from independent academic centers in the U.S., England, and China, point to excess levels of a protein called TNF as a key factor in AD. TNF is an immune signaling protein that regulates both inflammation and neuronal communication in the brain.

8 Nov 2010

Scientist sheds new light on cellular basis of neural impulse transmission

Neural impulse transmission and its effects on the functioning of the central nervous system (CNS) and peripheral nervous system (PNS) have always been in the forefront of discussion and studies, in the field of memory and behavioural changes.

8 Nov 2010

Central Nervous System News and Research

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Research suggests targeting spleen may promote healing of spinal cord injury

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

Adeona third quarter total net revenues increase to $289,898

Study finds extensive natural recovery after spinal cord injury

Research may lead to new treatment options for spinal cord injuries

Neurologix third quarter net loss decreases to $2.3 million

IBEC researchers discover new group of interacting partners for myelin-associated receptors

Amorfix second quarter net loss decreases to $25,728

Archives of Physical Medicine and Rehabilitation publishes articles on TBI

GPR124 protein controls growth of blood vessels into brains

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Excess levels of TNF immune signaling protein key factor in AD

Scientist sheds new light on cellular basis of neural impulse transmission

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News